FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035862891> ?p ?o ?g. }

• W3035862891 endingPage "114103" @default.
• W3035862891 startingPage "114103" @default.
• W3035862891 abstract "Janus kinase (JAK) inhibitors (also termed Jakinibs) constitute a family of small drugs that target various isoforms of JAKs (JAK1, JAK2, JAK3 and/or tyrosine kinase 2 (Tyk2)). They exert anti-inflammatory properties linked, in part, to the modulation of the activation state of pro-inflammatory M1 macrophages. The exact impact of JAK inhibitors on a wider spectrum of activation states of macrophages is however still to be determined, especially in the context of disorders involving concomitant activation of pro-inflammatory M1 macrophages and profibrotic M2 macrophages. This is especially the case in autoimmune pulmonary fibrosis like scleroderma-associated interstitial lung disease (ILD), in which M1 and M2 macrophages play a key pathogenic role. In this study, we directly compared the anti-inflammatory and anti-fibrotic effects of three JAK inhibitors (ruxolitinib (JAK2/1 inhibitor); tofacitinib (JAK3/2 inhibitor) and itacitinib (JAK1 inhibitor)) on five different activation states of primary human monocyte-derived macrophages (MDM). These three JAK inhibitors exert anti-inflammatory properties towards macrophages, as demonstrated by the down-expression of key polarization markers (CD86, MHCII, TLR4) and the limited secretion of key pro-inflammatory cytokines (CXCL10, IL-6 and TNFα) in M1 macrophages activated by IFNγ and LPS or by IFNγ alone. We also highlighted that these JAK inhibitors can limit M2a activation of macrophages induced by IL-4 and IL-13, as notably demonstrated by the down-regulation of the M2a associated surface marker CD206 and of the secretion of CCL18. Moreover, these JAK inhibitors reduced the expression of markers such as CXCL13, MARCO and SOCS3 in alternatively activated macrophages induced by IL-10 and dexamethasone (M2c + dex) or IL-10 alone (M2c MDM). For all polarization states, Jakinibs with inhibitory properties over JAK2 had the highest effects, at both 1 μM or 0.1 μM. Based on these in vitro results, we also explored the effects of JAK2/1 inhibition by ruxolitinib in vivo, on mouse macrophages in a model of HOCl-induced ILD, that mimics scleroderma-associated ILD. In this model, we showed that ruxolitinib significantly prevented the upregulation of pro-inflammatory M1 markers (TNFα, CXCL10, NOS2) and pro-fibrotic M2 markers (Arg1 and Chi3L3). These results were associated with an improvement of skin and pulmonary involvement. Overall, our results suggest that the combined anti-inflammatory and anti-fibrotic properties of JAK2/1 inhibitors could be relevant to target lung macrophages in autoimmune and inflammatory pulmonary disorders that have no efficient disease modifying drugs to date." @default.
• W3035862891 created "2020-06-25" @default.
• W3035862891 creator A5007844164 @default.
• W3035862891 creator A5014863527 @default.
• W3035862891 creator A5038293102 @default.
• W3035862891 creator A5047683324 @default.
• W3035862891 creator A5050027025 @default.
• W3035862891 creator A5056220939 @default.
• W3035862891 creator A5064627425 @default.
• W3035862891 creator A5070498798 @default.
• W3035862891 creator A5071882234 @default.
• W3035862891 creator A5073599067 @default.
• W3035862891 creator A5089633232 @default.
• W3035862891 creator A5089642757 @default.
• W3035862891 date "2020-08-01" @default.
• W3035862891 modified "2023-10-18" @default.
• W3035862891 title "Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease" @default.
• W3035862891 cites W1490888491 @default.
• W3035862891 cites W1922622904 @default.
• W3035862891 cites W1985859986 @default.
• W3035862891 cites W1993540575 @default.
• W3035862891 cites W2001519848 @default.
• W3035862891 cites W2059200513 @default.
• W3035862891 cites W2079645940 @default.
• W3035862891 cites W2123414080 @default.
• W3035862891 cites W2123633897 @default.
• W3035862891 cites W2145557630 @default.
• W3035862891 cites W2149189075 @default.
• W3035862891 cites W2153414586 @default.
• W3035862891 cites W2209250550 @default.
• W3035862891 cites W2311464222 @default.
• W3035862891 cites W2340617824 @default.
• W3035862891 cites W2347093301 @default.
• W3035862891 cites W2519748203 @default.
• W3035862891 cites W2532500892 @default.
• W3035862891 cites W2544907814 @default.
• W3035862891 cites W2588044396 @default.
• W3035862891 cites W2601173074 @default.
• W3035862891 cites W2611683578 @default.
• W3035862891 cites W2736034593 @default.
• W3035862891 cites W2740576013 @default.
• W3035862891 cites W2767445094 @default.
• W3035862891 cites W2774701909 @default.
• W3035862891 cites W2793794510 @default.
• W3035862891 cites W2802540563 @default.
• W3035862891 cites W2804542506 @default.
• W3035862891 cites W2805489776 @default.
• W3035862891 cites W2807718031 @default.
• W3035862891 cites W2883936429 @default.
• W3035862891 cites W2885429255 @default.
• W3035862891 cites W2890306273 @default.
• W3035862891 cites W2893388188 @default.
• W3035862891 cites W2900461074 @default.
• W3035862891 cites W2911875239 @default.
• W3035862891 cites W2912291998 @default.
• W3035862891 cites W2916037465 @default.
• W3035862891 cites W2945521814 @default.
• W3035862891 cites W2948359643 @default.
• W3035862891 cites W2955354003 @default.
• W3035862891 cites W2963254827 @default.
• W3035862891 cites W2965011046 @default.
• W3035862891 cites W2965426852 @default.
• W3035862891 cites W2969916059 @default.
• W3035862891 cites W2991146640 @default.
• W3035862891 cites W2994986833 @default.
• W3035862891 cites W3000099030 @default.
• W3035862891 cites W3004919484 @default.
• W3035862891 cites W3007102660 @default.
• W3035862891 cites W3008900858 @default.
• W3035862891 cites W3009803846 @default.
• W3035862891 cites W3013398484 @default.
• W3035862891 cites W3013570869 @default.
• W3035862891 cites W3013843138 @default.
• W3035862891 cites W3014462878 @default.
• W3035862891 cites W3016116890 @default.
• W3035862891 cites W4211001791 @default.
• W3035862891 cites W4213245349 @default.
• W3035862891 cites W4240886158 @default.
• W3035862891 doi "https://doi.org/10.1016/j.bcp.2020.114103" @default.
• W3035862891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32562787" @default.
• W3035862891 hasPublicationYear "2020" @default.
• W3035862891 type Work @default.
• W3035862891 sameAs 3035862891 @default.
• W3035862891 citedByCount "66" @default.
• W3035862891 countsByYear W30358628912020 @default.
• W3035862891 countsByYear W30358628912021 @default.
• W3035862891 countsByYear W30358628912022 @default.
• W3035862891 countsByYear W30358628912023 @default.
• W3035862891 crossrefType "journal-article" @default.
• W3035862891 hasAuthorship W3035862891A5007844164 @default.
• W3035862891 hasAuthorship W3035862891A5014863527 @default.
• W3035862891 hasAuthorship W3035862891A5038293102 @default.
• W3035862891 hasAuthorship W3035862891A5047683324 @default.
• W3035862891 hasAuthorship W3035862891A5050027025 @default.
• W3035862891 hasAuthorship W3035862891A5056220939 @default.
• W3035862891 hasAuthorship W3035862891A5064627425 @default.
• W3035862891 hasAuthorship W3035862891A5070498798 @default.
• W3035862891 hasAuthorship W3035862891A5071882234 @default.

• next